Tazemetostat (Standard)

Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2) -containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells[1].

Product Specifications

CAS Number

[1403254-99-8]

Product Name Alternative

EPZ-6438 (Standard) ; E-7438 (Standard)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Histone Methyltransferase; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Epigenetics; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tazemetostat-standard.html

Purity

99.72

Smiles

O=C(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(N(CC)C4CCOCC4)=C1C)NCC5=C(C)C=C(C)NC5=O

Molecular Formula

C34H44N4O4

Molecular Weight

572.74

Precautions

H302, H315, H319, H335

References & Citations

[1]Knutson SK, et, al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferaseEZH2. Proc Natl Acad Sci U S A. 2013 May 7;110 (19) :7922-7.